Lilly's Obesity Combination Posts 23% Weight Loss Signal — Phase 2 Promise Meets Phase 3 Uncertainty

Eli Lilly's Amylin-Zepbound Combo Shows Strong Phase 2 Weight Loss

Eli Lilly presented promising Phase 2 data at the European Association for the Study of Diabetes (EASD) meeting for its experimental combination of Zepbound (tirzepatide) and eloralintide for obesity. Over 48 weeks, the highest doses of the combination led to a 23% weight loss, or approximately 54 pounds, in people with obesity. This compared favorably to 15% weight loss for high-dose Zepbound alone and 12% for eloralintide alone, highlighting the potential for enhanced efficacy with the combination therapy.

• Eli Lilly's Phase 2 trial demonstrated that the combination of Zepbound and eloralintide achieved a substantial 23% average weight loss (approximately 54 pounds) over 48 weeks in individuals with obesity. This outcome surpassed the weight loss observed with either Zepbound (15%) or eloralintide (12%) administered as monotherapies, indicating a synergistic effect for greater efficacy.
• Analysts, such as David Risinger from Leerink Research, project significant sales for eloralintide, forecasting $23 billion by 2035. The drug, which stimulates amylin, is also being considered as a "softer" weight-loss option due to potentially fewer gastrointestinal side effects compared to other treatments, offering a differentiated profile in the competitive obesity market.
• The data suggests potential for flexible treatment strategies, with Evercore ISI's Umer Raffat proposing starting patients on the more tolerable eloralintide and subsequently adding Zepbound if greater weight loss is desired. This approach could optimize patient adherence and outcomes by tailoring treatment intensity to individual needs and tolerability profiles.

Eli Lilly's Zepbound-Eloralintide Combo Delivers Significant Weight Loss

Recent clinical evidence highlights meaningful advances in pharmacological weight management, with oral small-molecule GLP-1 receptor agonists and established injectable agents demonstrating significant efficacy across diverse patient populations. The studies below span Phase 2b through Phase 3 designs, capturing both glycemic and weight-related endpoints alongside safety profiles relevant to clinical and strategic decision-making.

Beyond GLP-1: Exploring New Targets and Delivery for Obesity

The obesity treatment landscape is rapidly expanding beyond GLP-1 receptor agonism, with research converging on multiple distinct biological axes — from adipose tissue remodeling to gut microbiota-endocrine crosstalk. Several mechanistically differentiated targets are demonstrating preclinical and early clinical promise, supporting a multi-pathway approach to addressing the heterogeneity of obesity as a disease.

• Amylin receptor agonism: Amylin, co-secreted with insulin from pancreatic β-cells, slows gastric emptying, suppresses glucagon secretion, and promotes meal termination through central mechanisms. Long-acting amylin analogs — including cagrilintide, eloralintide, petrelintide, MET-233i, ABBV-295, and AZD6234 — have demonstrated clinically meaningful weight loss with generally favorable tolerability profiles. Eloralintide (LY3841136), an AMY1R-selective agonist, showed dose-dependent weight loss in a Phase 1 trial, with week-4 mean percent change from baseline in body weight of -2.5% (p<0.01) and -4.4% (p<0.001) at single doses of 4 mg and 12 mg, respectively, versus +0.6% for placebo. Combination approaches such as cagrilintide with semaglutide (CagriSema) further extend this class's utility.

• Triple receptor agonism (GLP-1/GIP/glucagon): Retatrutide, a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, has demonstrated dose-dependent weight loss, reductions in HbA1c, and improvements in liver steatosis and diabetic kidney disease in Phase I and II clinical trials. Ongoing Phase III TRIUMPH studies are evaluating its long-term safety and efficacy across diverse patient populations.

• FGF21 and adipose browning: FGF21 regulates non-shivering thermogenesis (NST) via spatiotemporally distinct mechanisms. Acute cold exposure triggers hepatic FGF21 secretion through a β₃-adrenergic-lipolysis-PPARα axis, while chronic cold adaptation involves adipose-derived FGF21 signaling via the FGFR1/β-Klotho complex, activating the PLCγ-Ca²⁺-CREB pathway to enhance UCP1 expression and mitochondrial biogenesis. Clinically, full agonists of adipose FGFR1/β-Klotho signaling have demonstrated superiority over partial agonists, underscoring the importance of adipose-targeted FGF21 delivery for therapeutic efficacy.

• Gut microbiota-GDF15 axis: Red ginseng (RGS) administration in diet-induced obese mice enriched Akkermansia muciniphila, with its depletion abrogating RGS-mediated weight loss and appetite suppression. The A. muciniphila-derived protein Amuc_1631 was identified as a key effector promoting GDF15 secretion. Mechanistically, RGS upregulated colonic Gdf15 transcription via the PERK-eIF2α-ATF4-CHOP axis, activating the brainstem GDF15-GFRAL pathway to suppress food intake.

• Melanocortin 4 receptor (MC4R) pathway selectivity: MC4R-mediated suppression of food intake in the paraventricular nucleus of the hypothalamus (PVN) is primarily mediated by G(q/11)α rather than G(s)α. PVN-specific loss of G(q)α and G11α produces severe hyperphagic obesity and increased linear growth without affecting energy expenditure or glucose metabolism, identifying G(q/11)α-biased MC4R agonists as a potential selective therapeutic strategy for appetite regulation.

• MetAP2 inhibition in brown adipose tissue: Methionine aminopeptidase 2 (MetAP2) inhibitors reduce body weight and fat mass in obese mice by enhancing β-adrenergic-signaling-stimulated activities directly in brown adipocytes — including norepinephrine-induced lipolysis, UCP1 gene expression, and energy expenditure — while also prolonging norepinephrine activity in desensitized brown adipocytes.

• Natural compound-mediated fat browning: Coixol and sinigrin, derived from Coix lacryma-jobi L. and Raphanus sativus L. respectively, upregulated browning markers (UCP1, PGC-1α, PRDM16) and beige fat genes (Cd137, Cidea, Fgf21, Tbx1, Tmem26) in 3T3-L1 adipocytes. Fat browning was mechanistically associated with β3-adrenergic receptor activation and AMPK phosphorylation, positioning these compounds as candidate natural anti-obesity agents.

Shaping the Future: The Evolving Obesity Treatment Landscape

The past five years have seen a marked shift in the obesity pharmacotherapy landscape, driven by robust randomized controlled trial data supporting the efficacy of incretin-based agents in non-diabetic adults with overweight or obesity. Subcutaneous semaglutide, a GLP-1 receptor agonist, demonstrated a mean body weight reduction of -11.85% versus placebo (95% CI: -12.81 to -10.90; P < .00001) across four RCTs involving 3,613 participants, alongside significant improvements in waist circumference, BMI, and cardiometabolic risk factors including blood pressure and lipid profiles. Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, has since raised the efficacy bar further: meta-analyses of six RCTs in non-diabetic individuals with overweight or obesity reported a percentage body weight change of -16.32% (95% CI: -18.35 to -14.29) and an absolute weight reduction of -13.95 kg (95% CI: -18.83 to -9.07) versus placebo, with a clear dose-response relationship (meta-regression β = -0.72% per 1 mg increase; p = 0.0014). The SURMOUNT program additionally demonstrated durable weight reduction with clinically relevant improvements in waist circumference, blood pressure, triglycerides, and inflammatory biomarkers over long follow-up.

Beyond weight reduction, the field has increasingly focused on cardiovascular and cardiorenal outcomes. In non-diabetic adults with obesity, a meta-analysis of 11 RCTs found that GLP-1 RAs reduced MACE risk by 32% (RR 0.68; 95% CI: 0.53–0.87; P = 0.002), while tirzepatide was associated with a 59% reduction (RR 0.41; 95% CI: 0.18–0.92; P = 0.03). In obesity-related HFpEF specifically, the SUMMIT trial demonstrated reductions in worsening heart failure events and improvements in health status with tirzepatide, supporting a phenotype-specific role in heart failure management. GLP-1 RAs have also shown consistent reductions in HbA1c with minimal hypoglycemic risk, improvements in endothelial function, reductions in atrial natriuretic peptide production contributing to lower blood pressure, and statistically significant effects on LDL cholesterol — collectively repositioning these agents as integrated cardiometabolic therapies rather than weight-loss drugs alone.

The landscape has also expanded to include oral formulations and novel non-peptide agents, introducing new dimensions of comparative effectiveness. An indirect treatment comparison between oral semaglutide 25 mg and orforglipron 36 mg — informed by OASIS 4 and ATTAIN-1 — showed that oral semaglutide produced a significantly greater percentage change from baseline in body weight, with mean differences of -3.2%-points (95% CI: -5.9, -0.4; treatment-regimen estimand) and -3.0%-points (95% CI: -5.8, -0.3; efficacy estimand). Discontinuation due to any adverse event (OR: 4.1; 95% CI: 1.3, 13.0) and due to gastrointestinal adverse events (OR: 13.9; 95% CI: 2.0, 96.0) was higher with orforglipron. Across all agents, gastrointestinal adverse events — including nausea, vomiting, diarrhea, and constipation — remain the predominant tolerability concern, with real-world data indicating that GI adverse event profiles differ meaningfully between agents. Treatment discontinuation due to adverse events was significantly higher with semaglutide versus placebo (RR 2.62; 95% CI: 1.70–4.03; P = .001), though serious adverse events such as acute pancreatitis and cholelithiasis remained uncommon. These evolving data collectively underscore the need for agent-level differentiation in clinical and strategic decision-making as the obesity treatment class continues to mature.

Multi-Pathway Synergy: Lilly's Combo Reshapes Obesity Treatment

The recent Phase 2 data presented by Eli Lilly for its experimental combination of Zepbound (tirzepatide) and eloralintide marks a potentially transformative moment in obesity pharmacotherapy. Achieving an impressive 23% weight loss over 48 weeks, or approximately 54 pounds, this combination significantly outperforms either agent alone (15% for tirzepatide, 12% for eloralintide). This level of efficacy approaches or even exceeds that seen with some bariatric surgical interventions, offering a powerful non-surgical option for patients struggling with obesity.

This breakthrough is rooted in a sophisticated multi-pathway approach. Tirzepatide acts as a dual GIP and GLP-1 receptor agonist, while eloralintide is a novel, selective amylin 1 receptor (AMY1R) agonist. Research has consistently shown that combining incretin-based therapies with amylin receptor agonists can yield synergistic effects, leading to enhanced weight reduction and improved metabolic parameters. This strategic combination targets multiple physiological mechanisms involved in appetite regulation and energy expenditure, offering a more comprehensive attack on the complex pathophysiology of obesity.

For Eli Lilly, this data reinforces its strong position in the burgeoning obesity market, potentially setting a new benchmark for efficacy. The superior weight loss achieved could differentiate this combination from existing monotherapies, attracting patients who require more aggressive intervention or those who have not achieved optimal results with current treatments. However, several considerations remain. While eloralintide monotherapy has shown favorable tolerability, the combination of two potent agents could lead to increased gastrointestinal adverse events, potentially impacting long-term patient adherence. Furthermore, studies with tirzepatide monotherapy indicate that weight regain can occur upon treatment cessation, highlighting the critical need for sustained therapy or robust maintenance strategies. Finally, the likely higher cost of a dual-agent combination therapy could present access challenges, necessitating careful consideration of cost-effectiveness and payer strategies. Ultimately, this development underscores the shift towards personalized, mechanism-based combination therapies to optimize long-term outcomes in obesity management.